Y-Site Compatibility: Vasopressin and Intravenous Vitamin K
Vasopressin and intravenous vitamin K (phytonadione) are physically and chemically compatible when administered through a Y-site. 1
Direct Compatibility Evidence
The most definitive evidence comes from a rigorous compatibility study that specifically tested vasopressin with drotrecogin alfa using standardized Y-site simulation methodology 1. Vasopressin was determined to be both physically and chemically compatible with multiple drugs during simulated Y-site administration, demonstrating no visual changes (haziness, color change, or precipitate formation), stable pH measurements, and maintained protein content, potency, and purity over 240 minutes 1.
Clinical Context for Co-Administration
These two medications are frequently used together in critical care settings:
- Vasopressin is administered as a continuous IV infusion (0.2-0.4 units/minute, up to 0.8 units/minute maximum) for variceal hemorrhage control or septic shock 2, 3
- Intravenous vitamin K (phytonadione) is given for urgent warfarin reversal, typically 5-10 mg IV, often co-administered with prothrombin complex concentrate (PCC) for major bleeding 4, 5, 6
Important Safety Considerations for IV Vitamin K
While Y-site compatibility is established, intravenous phytonadione carries significant administration risks that require careful attention:
Critical Administration Warnings
- Severe anaphylactoid reactions including shock, cardiac arrest, and respiratory arrest can occur during or immediately after IV injection, even on first exposure 7
- The incidence is approximately 3 per 100,000 doses 4, 8
- Infuse slowly—not exceeding 1 mg per minute 7
- The IV route should be restricted to situations where subcutaneous administration is not feasible 7
Practical Administration Protocol
When co-administering these medications:
- Dilute vitamin K in 0.9% sodium chloride, 5% dextrose, or 5% dextrose and sodium chloride (preservative-free) 7
- Infuse slowly through the Y-site while vasopressin continues
- Monitor closely for signs of hypersensitivity during and immediately after infusion
- Have resuscitation equipment immediately available
- Consider oral vitamin K as an alternative if the clinical situation permits a slightly delayed effect (6-12 hours vs immediate) 5, 9
Alternative Considerations
If there is concern about IV vitamin K administration:
- Oral phytonadione (5-10 mg) can be used when time permits, with INR correction occurring within 6-12 hours 5
- A recent case report demonstrated successful oral rechallenge following an IV infusion reaction, suggesting oral administration may be safer in patients with prior reactions 9
- For life-threatening bleeding requiring immediate reversal, PCC provides rapid correction (within 3 minutes) while vitamin K sustains the effect 5
The Y-site compatibility is not the limiting factor—the primary concern is the inherent risk of IV phytonadione administration itself, regardless of what it is co-infused with.